GlassScriptPhysician profile
Stephanie Borgstrand
NPI 1659529931
$6,104.37
in general payments reported to CMS, 2019-2025
22 companies · $271 in 2025
The $271 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,627 · 2022: $1,279 · 2023: $1,375 · 2024: $1,553 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,934 · Travel and Lodging: $265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,933.79 |
| Travel and Lodging | $264.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,678.68 | 2021-2025 | Octrode, Proclaim, Prodigy |
| Spinal Simplicity, LLC | $402.43 | 2024 | Ha Minuteman G3-R, Liberty Si |
| Abbvie INC. | $352.95 | 2021-2024 | |
| Collegium Pharmaceutical, INC. | $220.82 | 2021-2023 | Belbuca |
| Biohaven Pharmaceutical Holding Company LTD. | $196.55 | 2022 | |
| Medtronic, INC. | $170.35 | 2021-2024 | Intellis Adaptivestim, Inceptiv, Vanta Adaptivestim |
| Amgen INC. | $162.09 | 2021-2023 | Enbrel, Otezla |
| Biohaven Pharmaceuticals, INC. | $154.75 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $150.39 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $136.90 | 2022-2023 | Relistor |
| Pfizer INC. | $87.15 | 2021-2023 | |
| Bioventus LLC | $64.17 | 2024 | Durolane |
| Ibsa Pharma INC. | $54.94 | 2021-2023 | Tirosint, Licart |
| Baudax Bio INC. | $50.07 | 2021 | |
| Grt US Holding, INC. | $49.33 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $37.08 | 2021 | |
| Forte Bio-Pharma LLC | $34.89 | 2021 | |
| Upsher-Smith Laboratories LLC | $22.94 | 2022 | |
| Spr Therapeutics, INC | $22.40 | 2024 | Sprint Pns System |
| Azurity Pharmaceuticals, INC. | $22.17 | 2024 | Horizant |
| Redhill Biopharma INC. | $20.51 | 2022 | |
| Biodelivery Sciences International, INC. | $12.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Borgstrand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.